EXHIBIT EVoting Agreement • May 14th, 2003 • MPM Bio Ventures Iii Lp • Pharmaceutical preparations • Delaware
EXHIBIT BWarrant Purchase Agreement • May 14th, 2003 • MPM Bio Ventures Iii Lp • Pharmaceutical preparations • California
EXHIBIT DRights Agreement • May 14th, 2003 • MPM Bio Ventures Iii Lp • Pharmaceutical preparations • California
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • February 12th, 2009 • MPM Bioventures Iii Lp • Pharmaceutical preparations
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Somaxon Pharmaceuticals, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • February 5th, 2015 • MPM Bioventures Iii L.P. • Pharmaceutical preparations
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of KaloBios Pharmaceuticals, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • February 13th, 2017 • MPM Bioventures Iii L.P. • Pharmaceutical preparations
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Vaccinogen, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.
EXHIBIT AMPM Bio Ventures Iii Lp • May 14th, 2003 • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of stock of Rigel Pharmaceuticals, Inc.
